Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 85 (8), 2147-53

Predictive Value for Treatment Outcome in Acute Myeloid Leukemia of Cellular Daunorubicin Accumulation and P-glycoprotein Expression Simultaneously Determined by Flow Cytometry

Affiliations
  • PMID: 7536492

Predictive Value for Treatment Outcome in Acute Myeloid Leukemia of Cellular Daunorubicin Accumulation and P-glycoprotein Expression Simultaneously Determined by Flow Cytometry

A Guerci et al. Blood.

Abstract

To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML). IDA and P-gp expression were determined by double-labeling flow cytometry analysis. Of 87 patients, 36 expressed P-gp (41%). P-gp expression was more frequently observed in AML at relapse and MDS-AML as compared with de novo AML (P = .0001). P-gp expression was significantly associated with CD34 expression (P = .0003) and chromosome 7 abnormalities (P = .027). A significantly reduced IDA was observed in P-gp+ as compared with P-gp- patients (P = .0007). Of the 87 patients, 51 achieved complete remission (CR). A reduced IDA was observed in patients in failure as compared with patients in CR (22% +/- 17% v 42% +/- 21%; P = 10(-4). Twelve of 36 P-gp+ patients as compared with 40 of 51 P-gp- patients achieved CR (33% v 78%; P = 10(-4). The prognostic value of IDA and P-gp expression was confirmed in multivariate analysis. These data suggest that the determination of IDA and P-gp expression may be useful in designing therapy for patients with AML.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback